Skip to main content

Aldosterone

  • Chapter
  • First Online:
Textbook of Vascular Medicine

Abstract

Aldosterone is a vitally important factor in cardiovascular homeostasis. Tightly regulated control of the biosynthesis and action of this mineralocorticoid hormone are crucial given that its excessive secretion, as seen in primary aldosteronism (PA), can result in severe hypertension, extensive organ damage and various comorbidities. The individual and societal consequences of this are huge: PA is currently held to account for ~15% of all hypertensive patients, but, due to difficulties in its accurate diagnosis, even this figure is likely to be an underestimate. Many patients are therefore currently classified as essential hypertensives and are receiving suboptimal treatment. Greater understanding of the regulatory systems governing aldosterone biosynthesis and action is therefore likely to be of huge benefit, leading to improved diagnostics, identification of informative biomarkers and development of better treatments more accurately targeted at the sizeable subsection of hypertensive patients most likely to benefit.

In this article we describe the major factors governing aldosterone biosynthesis and action in normal physiology and disease while also summarising significant recent advances in our understanding of PA and other promising current areas of research. It is our intention that this will provide insights into the highly dynamic state of current aldosterone research and the very real potential for game-changing treatments to counter the causes and consequences of excess aldosterone in the near future.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Connell JMC, MacKenzie SM, Freel EM, Fraser R, Davies E. A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function. Endocr Rev. 2008;29:133–54.

    Article  CAS  Google Scholar 

  2. Miller WL, Auchus RJ. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev. 2011;32:81–151.

    Article  CAS  Google Scholar 

  3. Bollag WB. Regulation of aldosterone synthesis and secretion. Compr Physiol. 2014;4:1017–55.

    Article  Google Scholar 

  4. Stowasser M, Gordon RD. Primary aldosteronism: changing definitions and new concepts of physiology and pathophysiology both inside and outside the kidney. Physiol Rev. 2016;96:1327–84.

    Article  CAS  Google Scholar 

  5. MacKenzie SM, Freel EM, Connell JM, Fraser R, Davies E. ACTH and polymorphisms at steroidogenic loci as determinants of aldosterone secretion and blood pressure. Int J Mol Sci. 2017;18:579.

    Article  Google Scholar 

  6. Markou A, Sertedaki A, Kaltsas G, et al. Stress-induced aldosterone hyper-secretion in a substantial subset of patients with essential hypertension. J Clin Endocrinol Metab. 2015;100:2857–64.

    Article  CAS  Google Scholar 

  7. MacKenzie SM, Connell JMC, Davies E. Non-adrenal synthesis of aldosterone: a reality check. Mol Cell Endocrinol. 2011;350:163–7.

    Article  Google Scholar 

  8. Takeda Y, Demura M, Wang F, et al. Epigenetic regulation of aldosterone synthase gene by sodium and angiotensin II. J Am Heart Assoc. 2018;7:e008281.

    Article  Google Scholar 

  9. Robertson S, MacKenzie SM, Alvarez-Madrazo S, Diver LA, Lin J, Stewart PM, Fraser R, Connell JM, Davies E. MicroRNA-24 is a novel regulator of aldosterone and cortisol production in the human adrenal cortex. Hypertension. 2013;62:572–8.

    Article  CAS  Google Scholar 

  10. Lenzini L, Caroccia B, Campos AG, et al. Lower expression of the TWIK-related acid-sensitive K+ channel 2 (TASK-2) gene is a hallmark of aldosterone-producing adenoma causing human primary aldosteronism. J Clin Endocrinol Metab. 2014;99:E674–82.

    Article  CAS  Google Scholar 

  11. Baker ME, Katsu Y. Evolution of the mineralocorticoid receptor: sequence, structure and function. J Endocrinol. 2017;234:T1–T16.

    Article  CAS  Google Scholar 

  12. Shibata S. Mineralocorticoid receptor and NaCl transport mechanisms in the renal distal nephron. J Endocrinol. 2017;234:T35–47.

    Article  CAS  Google Scholar 

  13. Chapman K, Holmes M, Seckl J. 11β-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action. Physiol Rev. 2013;93:1139–206.

    Article  CAS  Google Scholar 

  14. Ruhs S, Nolze A, Hübschmann R, Grossmann C. Nongenomic effects via the mineralocorticoid receptor. J Endocrinol. 2017;234:T107–24.

    Article  CAS  Google Scholar 

  15. Piaditis G, Markou A, Papanastasiou L, Androulakis II, Kaltsas G. Progress in aldosteronism: a review of the prevalence of primary aldosteronism in pre-hypertension and hypertension. Eur J Endocrinol. 2015;172:R191–203.

    Article  CAS  Google Scholar 

  16. Zennaro M-C, Boulkroun S, Fernandes-Rosa F. An update on novel mechanisms of primary aldosteronism. J Endocrinol. 2015;224:R63–77.

    Article  CAS  Google Scholar 

  17. McManus F, Sands W, Diver L, MacKenzie SM, Fraser R, Davies E, Connell JM. APEX1 regulation of aldosterone synthase gene transcription is disrupted by a common polymorphism in humans. Circ Res. 2012;111:212–9.

    Article  CAS  Google Scholar 

  18. Tesch GH, Young MJ. Mineralocorticoid receptor signaling as a therapeutic target for renal and cardiac fibrosis. Front Pharmacol. 2017;8:313.

    Article  Google Scholar 

  19. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709–17.

    Article  CAS  Google Scholar 

  20. DuPont JJ, Jaffe IZ. The role of the mineralocorticoid receptor in the vasculature. J Endocrinol. 2017;234:T67–82.

    Article  CAS  Google Scholar 

  21. Jia G, Habibi J, Aroor AR, Hill MA, Yang Y, Whaley-Connell A, Jaisser F, Sowers JR. Epithelial sodium channel in aldosterone-induced endothelium stiffness and aortic dysfunction. Hypertension. 2018;72:731–8. HYPERTENSIONAHA.118.11339

    Article  CAS  Google Scholar 

  22. Jia G, Aroor AR, Hill MA, Sowers JR. Role of renin-angiotensin-aldosterone system activation in promoting cardiovascular fibrosis and stiffness. Hypertension. 2018;122:624–38. HYPERTENSIONAHA.118.11065

    CAS  Google Scholar 

  23. Pitt B. Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies. Mol Cell Endocrinol. 2004;217:53–8.

    Article  CAS  Google Scholar 

  24. Kolkhof P, Bärfacker L. Mineralocorticoid receptor antagonists: 60 years of research and development. J Endocrinol. 2017;234:T125–40.

    Article  CAS  Google Scholar 

  25. Bernhardt R. The potential of targeting CYP11B. Expert Opin Ther Targets. 2016;20:923–34. 14728222.2016.1151873

    Article  CAS  Google Scholar 

  26. Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M, Young WF. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101:1889–916.

    Article  CAS  Google Scholar 

  27. Funder JW. Primary aldosteronism: the next five years. Horm Metab Res. 2017;49:977–83.

    Article  CAS  Google Scholar 

  28. Miller WL. Steroidogenesis: unanswered questions. Trends Endocrinol Metab. 2017;28:771–93.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

S.M.M., J.C.v.K. and E.D. are members of the ENS@T-HT EU-funded Horizon 2020 research and innovation project into hypertension and personalised treatments (► http://www.ensat-ht.eu).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Scott M. MacKenzie .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

MacKenzie, S.M., Cat, A.N.D., van Kralingen, J.C., Davies, E. (2019). Aldosterone. In: Touyz, R., Delles, C. (eds) Textbook of Vascular Medicine. Springer, Cham. https://doi.org/10.1007/978-3-030-16481-2_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-16481-2_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-16480-5

  • Online ISBN: 978-3-030-16481-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics